Issue: 56 Page: 28-33
Review of Medicinal Mushrooms Advances: Good News from Old Allies
by Solomon P. Wasser
HerbalGram. 2002; 56:28-33 American Botanical Council
Edible and medicinal mushrooms (macrofungi) not only can convert the huge
lignocellulosic biomass* waste into human food, but -- most remarkably -- can
produce notable mycopharmaceuticals, myconutriceuticals and mycocosmeceuticals.
The most significant aspect of mushroom cultivation, if
managed properly, is to create zero emission of lignocellulosic waste
materials. Mushroom biotechnological products have multibeneficial effects to
human welfare (e.g., as food, health tonics and medicine, feed and fertilizers,
and to protect and regenerate the environment). Pharmaceutical substances with
potent and unique health-enhancing properties were isolated recently from
medicinal mushrooms and distributed worldwide.2 Many of them are
pharmaceutical products, while others represent a novel class of dietary
supplements or "nutraceuticals." Several antitumor polysaccharides, such as
hetero-§-glucans and their protein complexes (e.g., xyloglucans, and acidic
§-glucan containing uronic acid) as well as dietary fiber, lectins, and
terpenoids, have been isolated from medicinal mushrooms. In Japan, China,
Russia, and Korea, several different polysaccharide antitumor drugs have been
developed from the fruiting bodies, mycelia, and culture media of various
medicinal mushrooms, such as shiitake (Lentinus edodes (Berk.) Sing., Tricholomataceae), reishi (Ganoderma lucidum (Curt.:Fr.) P. Karst., Ganodermataceae), turkey tail (Trametes versicolor (L.:Fr.)
Lloyd, Polyporaceae), split gill (Schizophyllum commune Fr.:Fr., Schizophyllaceae), mulberry yellow polypore (Phellinus linteus (Berk. et Curt.) Teng., Hymenochaetaceae), and chaga or cinder conk (Inonotus
obliquus (Pers.:Fr.) Pilat,
Hymenochaetaceae). The potential of medicinal mushrooms is enormous but mostly
untapped. It could and should evolve into a successful biotechnological
industry for the benefit of humankind.
The study of medicinal mushrooms through the last three decades
has proved its many beneficial outcomes and has been followed by the rapid
development of manufacturing businesses dealing with commercial cultivation of
mushrooms. In 1999, world production of mushrooms amounted to US$18 billion,
roughly equal to the value of coffee sales.3,4
Medicinal mycology has deep and firm roots in fungi's
traditional uses in the medicine of the Far East. For centuries, Chinese and
other healthcare practitioners employed mushrooms to treat various diseases.
They valued the power of some mushrooms as divine (e.g., a special goddess was
associated with the reishi mushroom). Reishi is also considered a symbol of
happy augury and good future, good health, longevity, and even life with the
immortals. The use of medicinal
mushrooms has gone beyond medicine itself: different schools of Taoism employed
reishi and other mushrooms as purifiers and promoters of mind and spirit.5
Only at the end of the 1960s did Eastern and Western scientists start to investigate the
mechanisms of the health effects of mushrooms. The first successful research
discovered the antitumor effects of hot water extracts from several mushroom
species.6 The main active components proved to be polysaccharides,
specifically §-D-glucans. Chihara and his co-workers7 isolated from
the fruiting bodies of shiitake a water-soluble antitumor polysaccharide, which
was named "lentinan" after the generic name of this mushroom. This was a major
discovery. Lentinan demonstrated powerful antitumor activity; preventing
chemical and viral tumor development in mice and experimental models.8,9
Polysaccharides displaying remarkable antitumor activity in
vivo (i.e., through screening against
sarcoma 180 in mice using intraperitoneal or oral methods of administration)
have been isolated from various species of mushrooms belonging to the orders
Auriculariales, Tremellales, Polyporales, and Gasteromycetales.2,6,8,10-13
Since the discovery of lentinan, several antitumor
polysaccharide agents have been developed and commercialized, using the submerged
cultured mycelial biomass of turkey tail (Krestin, PSK; Japan), and liquid
cultured broth product of split gill (Sonifilan, SPG, Schizophyllan; Japan).
These antitumor substances are regarded as biological response modifiers that
activate immunological responses. This basically means that:
1) they
cause no harm and place no additional stress on the body;
2) they
help the body to adapt to various environmental and biological stresses;
3) they
have nonspecific action on the body, supporting some or all of the major
systems, including nervous, hormonal, and immune systems, as well as regulatory
functions.
It is, indeed, fair to describe all major medicinal mushroom
preparations, both cellular compounds and secondary metabolites, as having weak
antigenicity and no side effects.
A very popular and effective preparation was developed from
turkey tail in Japan as early as 1965. A
polysaccharide-peptide from this mushroom, under the name Krestin (PSK), was developed from the strain
CM-101. It was approved for use against a number of cancers and was covered by the Japanese healthcare
plan. PSK exhibits a marked effect against different types of tumors in
experimental animals when administered intraperitoneally or orally. PSK
contains 75 percent glucan and 25 percent protein. In 1993, Krestin comprised
25 percent of the anticancer drug market in Japan, and sales totaled US$350
million.10,14 An analogous product under the name Polysaccharide
Peptide (PSP) was developed in China from turkey tail strain Cov-1; the development
process for this strain lasted nine years, from 1983 to 1992.15
Mizuno11 stated that, in general, a period of 10 years and a total
US$75 million, or 10 billion yen, are required from the beginning of
development of a new drug to the time it is marketed.
Another §-D-glucan developed and popular in Japan is
schizophyllan from split gill. It is especially effective against cervical
cancer.11 A glucan from mulberry yellow polypore was developed recently in Korea, and an
analogous polysaccharide biotechnology from this species has been accomplished
in Japan.16
Reishi, already mentioned as a sacred mushroom in ancient
China, has come to occupy a leading place in present-day medicinal mushroom
development. The market values of reishi-based natural healthcare products in
1995 were estimated as US$215 million in Taiwan, US$350 million in China,
US$600 million in Korea, and US$350 million in Japan.5 The
physiologically active substances of reishi are water-soluble polysaccharides
and alcohol-soluble triterpenoids. Today, 119 different triterpenoids are
identified in reishi,12 about 80 of which are biologically active.
Reishi dietary supplements (DS) are valued for their immunomodulating,
anticancer, antiviral properties. They are used during remission of cancer and
by hepatitis B patients. They also have anti-hyperlipidemic, hypotensive, and
hypoglycemic actions.17
Some 30 years ago, epidemiologists studying the native
population in the Piedade region in the suburbs of San Paulo, Brazil, noted
that the rate of occurrence of adult diseases was extremely low, and found an
association with the Agaricus species,
which was a part of the regular diet of the inhabitants of this area.18
This mushroom was identified as A. blazei Murr., known by common names royal sun Agaricus, himematsutake, kawarihaaratake, or
almond-flavored portobello. Experiments conducted in Japan with mice verified
that A. blazei significantly
activates the immune system.18 A number of immunity-enhancing,
anticancer, and antitumor fractions were isolated from A. blazei. This species was shown to be the most effective
anticancer mushroom in a study comparing its effects with shiitake, maitake (Grifola
frondosa (Dicks.:Fr.) S.F. Gray,
Polyporaceae), reishi, and other medicinal mushrooms. Fractions identified with
immune effects include polysaccharides, (1®6)-(1®3)-b-D-glucans,
(1®6)-(1®4)-b-D-glucans, polysaccharide-protein complex
(ATOM), RNA-protein complexes, and glucomannan.13,18-23
The Japan Cancer Association proved that A. blazei is effective against Ehrlich's ascites carcinoma,
sigmoid colon cancer, ovarian cancer, breast cancer, lung cancer, and liver
cancer, as well as against solid cancers.18
Higher Basidiomycetes mushrooms contain a large amount of
well-balanced essential amino acids. Dietary fibers are abundant in the tissue
of all mushrooms; they absorb bile acids or hazardous materials in the
intestine, and thus decrease the chances of carcinogenic and other poisoning.
The overall harmonizing effect of a diet balanced with mushroom, so highly
praised by the ancient Chinese, is not a myth, but is continually supported by
modern scientific investigations.
Several other health-promoting effects of the mushrooms
should not be overlooked. Not only polysaccharides and triterpenoids are known
as biologically active; wide ranges of substances from higher Basidiomycetes
belonging to different classes of chemical compounds have been described and
their medicinal properties evaluated. These substances represented glyco-
lipids (schizonellin), compounds derived from the shikimic acid (strobilurins
and oudemansins), aromatic phenols (drosophilin, armillasirin, omphalone),
fatty acid derivatives (filiboletic acid, podoscyphic acid), polyacetylenes
(agrocybin, xerulin), polyketides (caloporoside, hericenones A-H), nucleosides
(clitocine, nebularine), different sesquiterpenes (protoilludanes, marasmanes,
hirsutanes, caryophyllanes, etc.), diterpenes (cyathin, striatal),
sesterterpenes (aleurodscal), and many other substances of different origin.2,10,24
Biologically active substances from higher Basidiomycetes possess
antifungal, antibacterial, and antiviral properties; they can be used as
insecticidal and nematocidal agents. In medicine they are used to
immunomodulate both humoral and cellular immune factors in the body.
Polyfunctional acidic
glucuronoxylomannan isolated from jelly mushrooms (Tremella spp., Tremellaceae), for instance, stimulates vascular endothelial cells, possesses
pronounced antiradiating effects, stimulates hematogenesis, demonstrates
antidiabetic, anti-inflammatory, hypocholesterolemic, anti-allergic activities,
and shows hepatoprotective effects. It can be recommended to improve
immunodeficiency, including that induced by AIDS, physical stress or aging, and
it prevents senile degeneration of microvessels, maintaining better blood
perfusion conditions in vital organs.4
Most mushroom-derived preparations and substances find their
use not as pharmaceuticals, but as a novel class of dietary supplements or
"nutraceuticals." A mushroom nutraceutical is a refined or partially refined
extract or dried biomass from either the mycelium or the fruiting body of the
mushroom, which is consumed in the form of capsules or tablets as a dietary
supplement (not a conventional food) and which has potential therapeutic
applications. Regular intake may enhance the immune responses of the human
body, thereby increasing resistance to disease, and in some cases, causing
regression of a disease state. The market value of mushroom DS products
worldwide is estimated at US$6 billion per year. The market value of reishi mushroom-based
DS alone in 1995 was estimated at more than US$1.628 billion.5
The safety of mushroom-based dietary supplements is further
enhanced through the following controls:
1. The overwhelming
majority of mushrooms used for production of DS are cultivated commercially
(and not gathered in the wild). This guarantees proper identification, and
pure, unadulterated products. In many cases it also means genetic uniformity.
This may also benefit conservation of biodiversity.
2. Mushrooms
are easily propagated vegetatively, and thus keep to one clone. The mycelium
can be stored for a long time, and the genetic and biochemical consistency may
be checked after a considerable period of time.
3. Many
edible and medicinal mushrooms are capable of growing in the form of mycelial
biomass in submerged cultures.4
This last aspect, in our experience, offers a promising
future for standardized production of safe mushroom-based DS. Submerged culture
and semi-solid state fermentation has more consistent and predictable composition
than that of fruit bodies. For most substances, this mycelium biomass obtained
by submerged cultivation also has higher nutritional value. The culture media
in which mycelium grows are made of chemically pure and ecologically clean
substances. The cultivation of mushrooms for fruit body production is a
long-term process, taking one to several months for the first fruiting bodies
to appear, depending on species and substrate. By contrast, the growth of pure
mushroom cultures in submerged conditions in a liquid culture media permits
acceleration of the growth speed, resulting in biomass yield in several days.4
The additional advantage of submerged culturing is the fact that most
medicinal mushrooms do not produce fruiting bodies under commercial cultivation.
Reliable industrial cultivation techniques are known for only 37 mushroom
species,3 but medicinal mushrooms include many mycorrhizal or
parasitic species that need several years for development of normal fruiting
bodies on trees. Such species cannot be grown commercially, but their mycelia
can be grown easily and economically with the help of submerged culturing. High
stability and standardization of mycelium grown in submerged cultures is
important not only for producing DS, but also might be beneficial for producing
mushroom-based medicines.
The use of medicinal mushrooms goes hand in hand with
development of their artificial cultivation. The most significant aspect of
mushroom cultivation, if managed properly, is to create zero emissions (no
waste). Since more than 70 percent of agricultural and forest materials are
non-productive and are wasted in processing, this is a very real advantage.25
Many of these waste materials can be used as substrates to grow mushrooms. This
fact gives a basis to the opinion of many researchers in the field (including
this author) that sustainable development of mushrooms and their products in
the 21st century can become a "non-green revolution."3
Prof. Solomon P. Wasser is the Head of the International
Center for Cryptogamic Plants and Fungi, at the Institute of Evolution,
University of Haifa (Israel); and the Head of the Department of Cryptogamic
Plants, at the N.G. Kholodny Institute of Botany, National Academy of Sciences
of Ukraine.
Born and educated in Ukraine, Prof. Wasser earned his
advanced degrees at the N.G. Kholodny Institute of Botany, National Academy of
Sciences of Ukraine in Kiev. He was elected a member of the National Academy of
Sciences of Ukraine in 1988, and became Professor of Botany and Mycology in 1991.
He founded the International Center for Cryptogamic Plants and Fungi at the
Institute of Evolution in Haifa University in 1994 and has directed its work
since then. Since 2000, he has been a full Professor of Haifa University
(Israel).
In addition to his scientific studies, Prof. Wasser
performs a number of public and social activities. He is a founder and
editor-in-chief of three international journals, Algologia (Ukraine), International
Journal of Medicinal Mushrooms (USA) and International Journal on Algae (USA). He is an author and
co-author of 400 scientific publications, including 35 books and 12 patents.
References:
1. Idaho
National Engineering and Environmental Laboratory. INEEL Bioenergy Initiative.
2001 July. Available online: <http://www.inel.gov/energy/bioenergy/web-version-bioenergy-strategic-initiative-dnt-v2.pdf>
2. Wasser
SP, Weis AL. Medicinal properties of substances occuring in higher
Basidiomycetes mushrooms: Current perspectives [Review]. International
Journal of Medicinal Mushrooms
1999;1:31-62.
3. Chang
ST. Global impact of edible and medicinal mushrooms on human welfare in the
21st century: nongreen revolution. International Journal of Medicinal
Mushrooms 1999;1:1-8.
4. Wasser
SP, Nevo E, Sokolov D, Reshetnikov S, Timor-Tismenetsky M. Dietary supplements
from medicinal mushrooms: diversity of types and variety of regulations. International
Journal of Medicinal Mushrooms 2000;2:1-19.
5. Chang
ST, Buswell JA. Ganoderma lucidum
(Curt.:Fr.) P.Karst. (Aphyllophoromycetideae) - a mushrooming medicinal
mushroom. International Journal of Medicinal Mushrooms 1999;1:139-48.
6. Ikekawa
T, Uehara N, Maeda Y, Nakanishi M, Fukuoka F. Antitumor activity of aqueous
extracts of edible mushrooms. Cancer Res
1969;29:734-5.
7. Chihara
G, Maeda Y, Hamuro J, Sasaki T, Fukuoka F. Inhibition of mouse sarcoma 180 by
polysaccharides from Lentinus edodes (Berk.) Sing. Nature 1969;222:687-8.
8. Zakany J, Chihara G,
Fachet J. Effect of Lentinan on tumor growth in murine allogeneic and syngeneic
host. Int J Cancer 1980a;25:371-6.
9. Zakany
J, Chihara G, Fachet J. Effect of Lentinan on the production of migration
inhibitory factor induced by syngeneic tumor in mice. Int J Cancer 1980b;26:783-8.
10. Mizuno
T. The extraction and development of antitumor-active polysaccharides from
medicinal mushrooms in Japan [Review]. International Journal of Medicinal
Mushrooms 1999;1:9-30.
11. Mizuno
T. A development of antitumor polysaccharides from mushroom fungi. Food
& Food Ingred J (Japan).
1996;167:69-85.
12. Kim
HW, Kim BK. Biomedicinal triterpenoids of Ganoderma lucidum (Curt.:Fr.) P.Karst. (Aphyllophoromycetideae). International
Journal of Medicinal Mushrooms
1999;1:121-38.
13. Stamets
P. Growing Gourmet and Medicinal Mushrooms.
Berkeley/Toronto: Ten Speed Press; 2000.
14. Chang
ST. Mushroom biology: the impact on mushroom production and mushroom products.
In: Chang ST, Buswell JA, Chiu SW, et al,
editors. Mushroom Biology and Mushroom Products. Hong Kong: Chinese University Press; 1993. p. 3-20.
15. Hiroshi
S, Takeda M. Diverse biological activity of PSK (Krestin), a protein-bound
polysaccharide from Coriolus versicolor
(Fr.) Quel. In: Chang ST, Buswell JA, Chiu SW, et al, editors. Mushroom Biology and Mushroom Products.
Hong Kong: Chinese University Press; 1993. p. 237-245.
16. Mizuno
T. The development of an antitumor BRM from song gen, or meshimakobu, Phellinus
linteus (Berk. et Curt.) Teng mushroom
[Review]. International Journal of Medicinal Mushrooms 2000;2:21-34.
17. Wasser
SP, Weis AL. Medicinal mushrooms. In:
Nevo E, editor. Reishi Mushroom (Ganoderma lucidum (Curt.:Fr.) P.Karst.) Haifa, Israel: Peledfus; 1997.
p. 1-37.
18. Mizuno
T. 2002. Medicinal properties and clinical effects of Agaricus blazei Murr. International Journal of Medicinal
Mushrooms 2002;4 (forthcoming).
19. Mizuno
T, Hagiwara T, Nakamura T, Ito H, Shimura K, Sumiya T, Asakura A. Antitumor
activity and some properties of water-soluble polysaccharides from
"Himematsutake," the fruiting body of Agaricus blazei Murrill. Agricult Biol Chem 1990;54:2889-96.
20. Ito
H, Shimura K, Itoh H, Kawade M. Antitumor effects of a new
polysaccharide-protein complex (ATOM) prepared from Agaricus blazei (Iwade strain 101) "Himematsutake" and its
mechanisms in tumor-bearing mice. Anticancer Res 1997;17:277-84.
21. Fujimiya
Y, Suzuki Y, Oshiman K, Kobori K, Morigushi K, Nakashima H, Matumoto Y,
Takahara S, Ebina T, Katakura R. Selective tumoricidal effect of soluble
proteoglucan extracted from the basidiomycete, Agaricus blazei Murrill, mediated via natural killer cell activation
and apoptosis. Cancer Immunol Immunother 1998;46:147-59.
22. Fujimiya
Y, Yamamoto H, Niji M, Suzuki I. Peroral effect on tumor progression of soluble
beta (1,6)-glucans prepared by acid treatment from Agaricus blazei Murr. (Agaricaceae, Higher Basidiomycetes). International
Journal of Medicinal Mushrooms
2000;2:43-50.
23. Cho
SM, Lee Jh, Han SB, Kim BK. Chemical features and purification of
immunostimulating polysaccharides from the fruit bodies of Agaricus blazei. Korean J Mycol 1999;27:170-4.
24. Lorenzen
K, Anke T. Basidiomycetes as a source for new bioactive natural products. Curr
Org Chem 1998;2:329-64.
25. Poppe
J. Use of agricultural waste materials in the cultivation of mushrooms. In: Van
Griensven DLJL, editor. Science and cultivation
of edible fungi. Rotterdam/Brookfield: A.
Balkema; 2000. p. 3-24.
* Biomass
includes the full range of plants and plant-derived materials, such as
dedicated energy crops and trees, agricultural food and feed crops,
agricultural crop wastes and residues, wood wastes and residues, and municipal
wastes. The majority of non-food biomass is composed primarily of the natural
polymers cellulose, hemicellulose, and lignin and is referred to as
lignocellulosic biomass.
Lignocellulose
is a complex of lignin and cellulose present in the cell walls of woody plants.
Lignin is a complex organic polymer deposited in the cell walls of plants,
making them rigid and woody. Lignocellulosic material resource, like solar
energy, is sustainable. Lignocellulosic material is a kind of biomass that is
estimated to amount to 1.9x1011 tons of dry matter on land annually.1
|